Pfizer on a move to acquire Intercytex whish is a fully integrated cell technology platform for development of living, human cell-based technology for marketing into commercially viable market.
Intercytex has four products in development:
VAVELTA®, a skin repair and rejuvenation product intended to improve the appearance feel and function of damaged skin, commercially available in accredited centres in UK
SHEF-1, development of a stem cell line suitable for differentiation into retinal pigment epithelial (RPE) cells, this project is in collaboration with the London Project to Cure Blindness
ICX-SKN, being developed as a skin graft replacement for burns and acute wounds, Phase I trials completed
ICX-TRC, a hair regeneration product, in Phase II trials.
All Intercytex' products are derived from unmodified human cell.
Intercytex commenced operations in 2000 and currently employs around 50 staff. In addition to its head office in Cambridge, UK, it has its own GMP compliant clinical production facility plus research and development laboratories in Manchester, UK and a dedicated stem cell research laboratory in Sheffield, UK. Additional laboratories are located in Boston, US.
No comments:
Post a Comment